1. HIV Drug Resistance Mutations in Proviral DNA from a Community Treatment Program.
- Author
-
Derache, Anne, Shin, Hyoung-Shik, Balamane, Maya, White, Elizabeth, Israelski, Dennis, Klausner, Jeffrey D., Freeman, Alexandra H., and Katzenstein, David
- Subjects
THERAPEUTICS ,HIV infections ,DRUG resistance ,GENETIC mutation ,CD4 antigen ,COHORT analysis ,DRIED blood spot testing - Abstract
Background: Drug resistance mutations archived in resting memory CD4+ cells may persist despite suppression of HIV RNA to <50 copies/ml. We sequenced pol gene from proviral DNA among viremic and suppressed patients to identify drug resistance mutations. Methods: The Peninsula AIDS Research Cohort study enrolled and followed over 2 years 120 HIV infected patients from San Mateo and San Francisco Counties. HIV-1 pol genotyping by bulk sequencing was performed on 38 DNA and RNA from viremic patients and DNA only among 82 suppressed patients at baseline. Antiretroviral susceptibility was predicted by . Results: Among 120 subjects, 81% were on antiretroviral therapy and had been treated for a median time of 7 years. Thirty-two viremic patients showed concordant RNA and DNA genotypes (84%); the discordant profiles were mainly observed in patients with low-level viremia. Among suppressed patients, 21 had drug resistance mutations in proviral DNA (26%) with potential resistance to one, two or three ARV classes in 16, 4 and 1 samples respectively. Conclusions: The high level of genotype concordance between DNA and RNA in viremic patients suggested that DNA genotyping might be used to assess drug resistance in resource-limited settings, and further investigation of extracted DNA from dried blood spots is needed. Drug resistance mutations in proviral DNA in 26% of subjects with less than 50 copies/ml pose a risk for the transmission of drug resistant virus with virologic failure, treatment interruption or decreased adherence. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF